Respecting your elders: osimertinib demonstrates preferential activity in elderly patients with T790M positive non-small cell lung cancers

Схожие документы

• Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
  по: Mok, T.S., et al.
  Опубликовано: (2016)
• The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer
  по: Gao, Xin, et al.
  Опубликовано: (2016)
• Osimertinib in Indian patients with T790M-positive advanced nonsmall cell lung cancer
  по: Noronha, Vanita, et al.
  Опубликовано: (2017)
• Abivertinib in patients with T790M‐positive advanced NSCLC and its subsequent treatment with osimertinib
  по: Wang, Hanping, et al.
  Опубликовано: (2020)
• Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer
  по: Nanjo, Shigeki, et al.
  Опубликовано: (2018)